Tel.: 716-845-8447, Fax: 716-845-2343
1097-0215/asset/olbannerleft.jpg?v=1&s=45719cd7de57873027993264fcc568b335a8cd56)
1097-0215/asset/olbannerright.jpg?v=1&s=5e0fba63c1309b3036eb9215a0e1e83dd02efd19)
Cancer Therapy
Smoking adversely affects survival in acute myeloid leukemia patients†
Article first published online: 2 AUG 2011
DOI: 10.1002/ijc.26151
Copyright © 2011 UICC
Additional Information
How to Cite
Varadarajan, R., Licht, A. S., Hyland, A. J., Ford, L. A., Sait, S. N.J., Block, A. W., Barcos, M., Baer, M. R., Wang, E. S. and Wetzler, M. (2012), Smoking adversely affects survival in acute myeloid leukemia patients. Int. J. Cancer, 130: 1451–1458. doi: 10.1002/ijc.26151
- †
Dr. Varadarajan reviewed all the cases and wrote the article. Ms. Licht and Dr. Hyland performed the statistical analyses. Ms. Ford constructed the database. Drs. Sait and Block reviewed all the karyotype analyses. Dr. Barcos reviewed the pathology specimens. Dr. Baer contributed to the care of the patients. Dr. Wang contributed to the care of the patients. Dr. Wetzler oversaw the conduct of the study, contributed to the care of the patients and to the article preparation. All authors reviewed the final article and approved it.
Publication History
- Issue published online: 19 JAN 2012
- Article first published online: 2 AUG 2011
- Accepted manuscript online: 25 APR 2011 08:24AM EST
- Manuscript Accepted: 22 MAR 2011
- Manuscript Received: 4 JAN 2011
Funded by
- National Cancer Institute. Grant Number: CA16056
- Szefel Foundation
- Roswell Park Cancer Institute
- Nancy C. Cully Endowment for Leukemia Research
- Heidi Leukemia Research Fund, Buffalo, NY
Keywords:
- acute myeloid leukemia;
- smoking;
- treatment;
- outcome
Abstract
Smoking adversely affects hematopoietic stem cell transplantation outcome. We asked whether smoking affected outcome of newly diagnosed acute myeloid leukemia (AML) patients treated with chemotherapy. Data were collected on 280 AML patients treated with high-dose cytarabine and idarubicin-containing regimens at Roswell Park Cancer Institute who had smoking status data at diagnosis. Patients' gender, age, AML presentation (de novo vs. secondary), white blood cell (WBC) count at diagnosis, karyotype and smoking status (never vs. ever) were analyzed. Among the 161 males and 119 females with a median follow-up of 12.9 months, 101 (36.1%) had never smoked and 179 (63.9%) were ever smokers. The proportion of patients between never and ever smokers was similar to respect to age, AML presentation, WBC count at diagnosis or karyotype based on univariate analysis of these categorical variables. Never smokers had a significantly longer overall survival (OS) (60.32 months) compared to ever smokers (30.89; p = 0.005). In multivariate analysis incorporating gender, age, AML presentation, WBC count, karyotype and smoking status as covariates, age, karyotype and smoking status retained prognostic value for OS. In summary, cigarette smoking has a deleterious effect on OS in AML.